U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis

Clinical Infectious Diseases

Volumn 28, Issue 1, 1999, Pages 42-48

  Meyerhoff, Andrea ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ARTICLE; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOKALEMIA; HYPOTENSION; NEPHROTOXICITY; PRIORITY JOURNAL; RASH; VISCERAL LEISHMANIASIS;

EID: 0032991693     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515085     Document Type: Article

References (24)

1. Leishman WB. On the possibility of the occurrence of trypanosomiasis in India. Br Med J 1903;1:1252-4.
2. Centers for Disease Control and Prevention. Viscerotropic leishmaniasis in persons returning from Operation Desert Storm - 1990-91. MMWR Morb Mortal Wkly Rep 1992;41:131-3.
3. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997;10:298-319.
4. Pearson RD, de Queiroz Sousa A. Clinical spectrum of leishmaniasis. Clin Infect Dis 1996;22:1-13.
5. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46:296-306.
6. Torre-Cisneros J, Villanueva JL, Kindelan JM, Jurado R, Sanchez-Guijo P. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect Dis 1993;17:625-7.
7. Gokhale PC, Kshirsagar NA, Khan MU, et al. Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B. Trans R Soc Trop Med Hyg 1994;88:228.
8. Gradoni L, Bryceson A, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 1995;73:191-7.
9. Thakur CP, Kumar M, Kumar P, Mishra BN, Pandey AK. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomized study. Br Med J 1988;296:1557-61.
10. Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994;344:1599-600.
11. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997;24:684-703.
12. Davidson RN, Croft SL, Scott AG, Maini M, Moody AH, Bryceson ADM. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 1991;337:1061-2.
13. Dietze R, Milan EP, Berman JD, et al. Treatment of Brazilian kala-azar with a short course of Amphocil (amphotericin B cholesterol dispersion). Clin Infect Dis 1993;17:981-6.
14. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997;127:133-7.
15. Davidson RN, Di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in visceral leishmaniasis: a multi-centre trial. Q J Med 1994;87:75-81.
16. Davidson RN, di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996;22:938-43.
17. Russo R, Nigro LC, Minniti S, et al. Visceral leishmaniasis in HIV-infected patients: treatment with high-dose liposomal amphotericin B (AmBisome). J Infect 1996;32:133-7.
18. Seaman J, Boer C, Wilkinson R, et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995;21:188-93.
19. Chulay JD, Bryceson ADM. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983;32:475-9.
20. Thakur CP, Pandey AK, Sinha GP, et al. Comparison of three treatment regimens of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996;90:319-22.
21. Lopez-Dupla M, Gil-Aguado A, Lavilla-Uriol P, et al. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis: report of two cases. J Antimicrob Chemother 1993;32:657-9.
22. Office of the Federal Register, National Archives and Records Administration. U.S. Code of Federal Regulations [21 CFR 316.20]. Washington, DC: U.S. Government Printing Office, 1996.
23. Ephros M, Waldman E, Zilberstein D. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Antimicrob Agents Chemother 1997;41:1064-8.
24. Sereno D, Lemesre JL. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother. 1997;41:972-6.